<DOC>
	<DOCNO>NCT02802293</DOCNO>
	<brief_summary>The purpose study determine clinical effect ( ) connectivity-guided repetitive transcranial magnetic stimulation ( rTMS ) treatment major depressive disorder ( MDD ) provide clue ideal neural network target robust clinical outcome , identify potential biomarkers treatment response include change brain network connectivity .</brief_summary>
	<brief_title>Treatment Depression With Connectivity Guided Robotically Delivered rTMS</brief_title>
	<detailed_description>The investigator propose randomize , double-blind , 4-week trial rTMS leave dorsolateral prefrontal cortex ( DLPFC ) subject MDD concurrently receive pharmaceutical psychotherapeutic intervention . Arm 1 delivers active rTMS leave DLPFC use standard aim strategy . Arm 2 delivers active rTMS leave anterior DLPFC use connectivity-based , image-guided aiming . Arm 3 delivers active rTMS leave posterior DLPFC use connectivity-based , image-guided aiming . In three arm , rTMS administer image-guided , robotic manner ensure therapist blind equivalent subject experience across arm . In three arm , follow stimulation protocol use : 10 Hz rTMS deliver 4 sec train 26 sec inter-train interval , 37.5 minutes/session ( i.e . 3,000 pulses/session ) , 5 sessions/week , 4 week . Neuroimaging used treatment plan characterize rTMS-induced network plasticity use resting-state functional magnetic resonance imaging ( rs-fMRI ) week 4 treatment arm . Clinical assessment neuropsychological test administer weekly throughout treatment ( week 1-4 ) .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<criteria>1 . Males females MDD receive treatment Laurel Ridge Treatment Center ( LRTC ) age 1865 year . 2 . Meeting fifth edition Diagnostic Statistical Manual Mental Disorders ( DSMV ) criteria MDD determine use MiniInternational Psychiatric Interview ( MINI ) . 3 . Meeting MontgomeryAshberg Depression Rating Scale ( MADRS &gt; 18 ) criterion treatment resistance MDD despite complete least one adequate trial Selective Serotonin Reuptake Inhibitor ( SSRI ) SerotoninNorepinephrine Reuptake Inhibitor ( SNRI ) FDArecommended dose least 68 week . 4 . Subjects SSRIs antidepressant , hypnotic medication include modulators GammaAminobutyric Acid ( GABA ) A receptor function , trazodone , atypical neuroleptic psychotropic medication prazosin may enter study deem stable dose medication . 5 . Able provide write informed consent . 6 . Able read write English . 1 . Subjects diagnostic history bipolar disorder , schizophrenia schizoaffective disorder currently exhibit psychotic feature confirm MINI . 2 . Serious , active suicidal risk assess evaluate psychiatrist . Serious active suicidal risk determine imminent risk suicide reflect subject plan intent end life . History suicidality exclusion participation protocol long evaluate psychiatrist determines absence serious active suicidal risk mean keep subject safe . 3 . Substance use disorder 3 month prior screen ; except Mild Moderate Alcohol Use Disorder accord DSM5 V criterion . 4 . Any history sign serious medical neurological illness include seizure disorder . Except seizure , subject clinical abnormality may include study clinician considers illness introduce additional risk interfere study procedure . 5 . History traumatic brain injury ( TBI ) loss consciousness 20 minute determine Brief Traumatic Brain Injury Screen ( TBI Screening Tool ) . 6 . Positive urine pregnancy test screening . 7 . Any history sign metal object ( e.g . surgical clip , cardiac pacemaker , metal implant , etc . ) body time screen . MRI risks person foreign body implant body .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Repetitive Transcranial Magnetic Stimulation</keyword>
	<keyword>Major Depressive Disorder</keyword>
</DOC>